Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblozyl, Camzyos, and Breyanzi.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback